Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcription profiling of response to tamoxifen in human ERa-positive postmenopausal breast tumor patients

ABSTRACT: Identification of HRPAP20 and TIMELESS as outstanding candidate markers to predict the response to tamoxifen in ERa-positive postmenopausal breast tumor patients

ORGANISM(S): Homo sapiens

SUBMITTER: Sengul Tozlu

PROVIDER: E-TABM-72 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Publications

Oligonucleotide microarray analysis of estrogen receptor alpha-positive postmenopausal breast carcinomas: identification of HRPAP20 and TIMELESS as outstanding candidate markers to predict the response to tamoxifen.

Tozlu-Kara S S Roux V V Andrieu C C Vendrell J J Vacher S S Lazar V V Spyratos F F Tubiana-Hulin M M Cohen P P Dessen P P Lidereau R R Bièche I I

Journal of molecular endocrinology 20071001 4

The estrogen receptor alpha (ER alpha) status of breast tumors is used to identify patients who may respond to endocrine agents such as tamoxifen. However, ER alpha status alone is not perfectly predictive, and there is a pressing need for more reliable markers of endocrine responsiveness. In this aim, we used a two-step strategy. We first screened genes of interest by a pangenomic 44 K oligonucleotide microarray in a series of ten ER alpha-positive tumors from five tamoxifen-treated postmenopau ...[more]

PMID: 17909269

Similar Datasets

Transcription profiling of non-small cell lung carcinoma cell line H1975 treated with cisplatin or BMS-69014 a novel panHER/VEGFR inhibitor

Project description:Non-small cell lung cancer (NSCLC) with activating mutations in the epidermal growth factor receptor (EGFR) responds to EGFR tyrosine kinase inhibitors such as erlotinib. However, secondary somatic EGFR mutations (e.g. T790M) confer resistance to erlotinib. BMS-690514, a novel panHER/VEGFR inhibitor described here, exerted antiproliferative and pro-apoptotic effects on NSCLC cell lines, with prominent efficacy on H1975 cells expressing the T790M mutation. In this model, BMS-690514 induced a G1 cell cycle arrest, as well as ultrastructural hallmarks of apoptosis, mitochondrial release of cytochrome c, and activation of caspases involved in the intrinsic (e.g. caspase -2, -3, -7 and -9), but not in the extrinsic (e.g. caspase-8) pathway. Caspase inhibition conferred partial protection against BMS-690514 cytotoxicity, pointing to the involvement of both caspase-dependent and -independent effector mechanisms. Transcriptome analyses revealed the upregulation of pro-apoptotic (e.g. Bim, Puma) and cell cycle inhibitory (e.g. p27Kip1, p57Kip2) factors, as well as the downregulation of anti-apoptotic (e.g. Mcl1), heat shock (e.g. HSP40, HSP70, HSP90) and cell cycle promoting (e.g. cyclins B1, D1 and D3, CDK1, MCM family proteins, PCNA) proteins. BMS-690514-induced death of H1975 cells was modified in a unique fashion by a panel of siRNAs targeting apoptosis modulators. Downregulation of components of the NF-kappaB survival pathway (e.g. p65, Nemo/IKK, TAB2) sensitized cells to BMS-690514, whereas knockdown of pro-apoptotic factors (e.g. Puma, Bax, Bak, caspase-2, etc) and DNA damage-related proteins (e.g. ERCC1, hTERT) exerted cytoprotective effects. BMS-690514 is a new pan-HER/VEGFR inhibitor that may become an alternative to erlotinib for the treatment of NSCLC.

2007-07-24 | E-TABM-239 | biostudies-arrayexpress

Transcription profiling of human T cell lines isolated from tumor infiltrating lymphocytes or peripheral blood lymphocytes of a patient with large cell carcinoma of the lung

Project description:The IGR-Heu tumor cell line was established from patient Heu suffering from large cell carcinoma of the lung. Heu171 T cell clones were isolated from autologous tumor infiltrating lymphocytes. H32-22 clone was isolated from autologous peripheral blood lymphocytes after stimulation with IGR-Heu and sorting with peptide-MHC tetramers. T cells were grown in the presence of irradiated autologous tumor and lymphoblastoid cell lines in complete media supplemented with rIL-2 and conditioned medium from phytohemagglutinin-activated lymphocytes for 3 weeks. Then, for microarray assays, RNA was extracted from the different cells

2007-03-02 | E-TABM-207 | biostudies-arrayexpress

Transcription profiling of human cell lines treated with cytochalasin D and nocodazole with the aim of characterising tetraploid clones

Project description:During the oncogenic process, tetraploidy is a candidate intermediate stage leading from diploidy to aneuploidy. The aim of our experiment was to establish tetraploid clones and to characterize their transcriptome.

2006-03-01 | E-TABM-70 | biostudies-arrayexpress

Transcription profiling of cohort of human cutaneous primary melanomas associated with a distant metastasis free survival

Project description:Identification of genomic characteristics in a cohorte of human cutaneous primary melanoma associated with a distant metastasis free survival.

2007-04-01 | E-TABM-1 | biostudies-arrayexpress

Transcription profiling of human cutaneous primary melanomas in an independent population of 17 patients

Project description:Validation of genomics characteristics of human cutaneous primary melanoma in an independnat population of 17 patients.

2007-04-01 | E-TABM-2 | biostudies-arrayexpress

Comparative genomic hybridization of 23 human nevi with a pool of primary cutaneous melanoma

Project description:Genomic profiles comparing 23 nevi with a pool of primary cutaneous melanoma

2009-04-16 | E-TABM-3 | biostudies-arrayexpress

Transcription profiling of 9 pairs of human metastasis/primary melanoma (each from the same patient)

Project description:Study by dye-swap of 9 pairs of metastasis/primary melanoma (each from the same patient)

2007-04-01 | E-TABM-4 | biostudies-arrayexpress

Transcription profiling of human diploid and tetraploid HCT116 cells treated with cisplatin and/or a Chk1 inhibitor to investigate resistance to genotoxic stress

Project description:Tetraploid cells are more resistant against genotoxic stress (irradiation, platinum compounds, topoisomerase inhibitors) than their diploid precursors. Here, we studied the effect of cisplatin and/or Chk1 inhibition on the transcriptome of diploid and tetraploid HCT116 cells

2008-06-09 | E-TABM-172 | biostudies-arrayexpress

Transcription profiling of humoral resistance to the CTL after phenotypical and functional study of the resistant clone IGR-HeuR8

Project description:From a tumoral line IGR-Heu; resulting from a biopsy of the primitive tumour of a patient reached of a bronchial cancer not with small cells (NSCLC); we established; by successive co-cultures of this line with the autologous CTL (clone T H161); a resistant line to the cytotoxic lysis induced by H161 (IGR-HeuR8 line). This resistant line was then cloned by limiting dilutions and a resistant clone was obtained (tumoral clone IGR-HeuR8). The goal of this study is to define profiles of genetic expression of the tumoral resistance to the CTL after phenotypical and functional study of the resistant clone IGR-HeuR8.

2006-01-23 | E-TABM-71 | biostudies-arrayexpress

Transcription profiling of human CD34+ cells from familial platelet disorder

Project description:Characterize the genes deregulated in CD34 positive cells from peripheral blood of FPD/AML patients harbouring two different RUNX1 mutations. RUNX1 (also called AML1), a DNA-binding subunit of the CBF transcription factor family, is a master regulatory gene in hematopoiesis and acts as a tumour suppressor. Heterozygous germ line alterations in RUNX1 lead to a familial platelet disorder with a propensity to develop acute myeloid leukemia (FPD/AML). Although RUNX1 abnormalities per se are not sufficient to induce full-blown leukemia in FPD, this pathology represents a valuable model to understand how RUNX1 germ line mutations predispose to acquisition of additional genetic changes leading to leukemia transformation. To investigate how RUNX1 may predispose to leukemia, we performed a comparative study between two pedigrees harbouring different RUNX1 mutations, one associated with only thrombocytopenia (R139stop) and the other leading to thrombocytopenia and leukemic predisposition (R174Q).

2010-09-11 | E-TABM-792 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data